---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-286169"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2024-12-30T23:59:59+00:00"
generated_at: "2026-05-28T22:45:56.938068+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IDEAYA licenses DLL3 ADC SHR-4849 from Hengrui; total potential payments $1.045B

## Summary
- Exclusive worldwide license (ex-Greater China) for Phase 1 DLL3-targeting Topo-I-payload ADC SHR-4849.
- Hengrui Pharma eligible for $75M upfront, up to $200M development/regulatory milestones, plus commercial milestones and mid-single to low-double digit royalties.
- In 11 evaluable SCLC patients at therapeutic doses, 8 partial responses observed (~73% ORR, including unconfirmed) with manageable safety profile.
- IDEAYA targets US IND filing for SHR-4849 in H1 2025; cash runway guided to at least 2028 unchanged.
- SHR-4849 offers rational combination opportunity with IDEAYA's Phase 1 PARG inhibitor IDE161 for enhanced preclinical efficacy.

## SEC filing metadata
- accession: 0001193125-24-286169
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2024-12-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000119312524286169/0001193125-24-286169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000119312524286169/d917390d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-286169
- JSON: https://secwatch.observer/filing/0001193125-24-286169.json
- Plain text: https://secwatch.observer/filing/0001193125-24-286169.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.